Article Text

PDF
C Integrated Allelic, Transcriptional, and Phenotypic Dissection of the Cardiac Effects of Titin Variation in Health and Diseaser
  1. AM Roberts1,2,3,4,*,
  2. J Ware2,3,5,6,
  3. D Herman5,6,
  4. S Schafer4,7,
  5. F Mazzarotto2,3,
  6. J Baksi2,3,
  7. R Buchan2,3,
  8. R Walsh2,3,
  9. S John2,3,
  10. S Wilkinson2,3,
  11. L Felkin2,3,
  12. A Bick5,6,
  13. M Radke8,
  14. M Gotthardt8,9,
  15. P Barton2,3,
  16. N Hubner7,9,10,
  17. J Seidman5,6,
  18. C Seidman5,6,11,
  19. S Cook2,3,4,11
  1. 1Clinical Sciences Centre, Imperial College London, UK
  2. 2NIHR Cardiovascular Biomedical Research Unit at Royal Brompton and Harefield NHS Foundation Trust and Imperial College London, UK
  3. 3National Heart and Lung Institute, Imperial College London, UK
  4. 4Duke-National University of Singapore, Singapore
  5. 5Department of Genetics, Harvard Medical School, Boston, USA
  6. 6Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
  7. 7Cardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine, Berlin, Germany
  8. 8Neuromuscular and Cardiovascular Cell Biology, Max Delbrück Center for Molecular Medicine, Berlin, Germany
  9. 9DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Germany
  10. 10Charité-Universitätsmedizin, Berlin, Germany
  11. 11Cardiovascular Division, Brigham and Women’s Hospital and Howard Hughes Medical Institute, USA
  12. 12National Heart Centre Singapore, Singapore
  13. *Presenting Author

Abstract

Introduction TTN truncating variants (TTNtv) cause severe dilated cardiomyopathy (DCM), but sometimes occur in healthy individuals, posing significant challenges for the interpretation of these variants in an era of accessible genome sequencing. The mechanism by which TTNtv impact clinical outcomes is poorly understood.

Methods Here, we integrated the power of quantitative cardiac MRI and capacity of next generation sequencing to assess the relationship between TTN genotype and cardiac phenotype. We sequenced TTN in 4,440 subjects including 308 healthy volunteers, 3,603 Framingham Heart Study (FHS) and Jackson Heart Study (JHS) participants, 374 prospective, unselected DCM cases and 155 end-stage retrospective DCM cases including 84 for whom left ventricular (LV) tissue was available for RNA and protein studies.

Results TTNtv were identified in 1.4% of controls (healthy volunteers, FHS and JHS participants), in 13% of unselected and 22% of end-stage DCM cases (OR 16.6, P = 4.8 × 10–45, DCM vs controls). More than 45% of controls have at least one rare TTN non-synonymous SNP (nsSNP). Rare and novel TTN nsSNPs were not enriched in DCM, either alone or in combination with a TTNtv (P = 0.8 (38.85% in DCM vs 38.24% in controls) suggesting that TTN nsSNPs are not an important cause of DCM. To improve TTN transcript annotations, we determined average cardiac TTN exon usage de novo from RNA-sequencing. TTNtv in DCM cases were enriched in highly utilised exons and isoforms (P = 2.5 × 10–4) compared to controls. We estimate that TTNtv in highly utilised exons have >93% probability of pathogenicity (likelihood ratio 14) in DCM cases. TTNtv-positive DCM patients had more depressed LV ejection fraction (LVEF:P = 0.02), thinner LV walls (P < 0.02), and a higher incidence of sustained ventricular tachycardia (P = 0.001).

C-terminus TTNtv were associated with lower LVEF vs N-terminus (β = -18 ± 7%, p = 0.006) and were more common in end-stage disease. No change was detected in total TTN mRNA or protein levels in TTNtv-positive hearts.

Conclusion TTNtv are the most common cause of DCM. TTN nsSNPs are not an important cause of DCM in the absence of other discriminating features. Incorporation of variant position and exon-specific expression improves interpretation of TTNtv. Most individuals with TTNtv do not develop DCM, but TTNtv in highly utilised, particularly distal exons commonly cause DCM with severely impaired LV function and life-threatening ventricular arrhythmias, likely through dominant-negative mechanisms. In DCM patients, presence and position of TTNtv may aid prognostication and management.

Abstract C Figure 1

TTNtv and survival in DCM. Outcomes in unselected DCM patients with (red) and without (blue) TTNtv. (Left) Age censored at adverse event (death, cardiac transplant or left-ventricular assist device (LVAD)) or at age 70 years. (Right) Adverse events after enrollment, to control for ascertainment (interval censored from time of enrollment to age 70 years or adverse event). Event free survival is reduced in TTNtv-positive DCM (P = 0.015) as a result of faster disease progression. A trend to younger presentation (Table 2), and worse outcomes after enrollment (P = 0.05) combine to give reduced survival overall

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.